• Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

    来源: Nasdaq GlobeNewswire / 26 2月 2024 08:00:00   America/New_York

    SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024.

    Details of the fireside chat can be found below.

    Presenter: Mark Erlander, CEO
    Date: March 4, 2024
    Time: 1:30 pm – 2:00 PM ET

    Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replays will be available after the conclusion of the respective presentations.

    About Cardiff Oncology, Inc.

    Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

    Cardiff Oncology Contact:
    James Levine
    Chief Financial Officer
    858-952-7670
    jlevine@cardiffoncology.com

    Investor Contact:
    Kiki Patel, PharmD 
    Gilmartin Group
    332-895-3225
    Kiki@gilmartinir.com

    Media Contact:
    Richa Kumari
    Taft Communications
    551 344-5592 
    richa@taftcommunications.com


分享